However, while blocking the PD-1/PD-L1 pathway has shown significant therapeutic benefits for various cancers, the effectiveness of ICIs in treating CRC is limited, benefiting only a small subset of patients [83]. This evidence concerns the gene CD274 and colorectal carcinoma.